Indeed, we have recently demonstrated that co-existing hypertension increased arrhythmia risk and reduced the efficacy of pacemaker treatment in carriers of the SCN5A-1795insD mutation above the age of 40 years. This evidence concerns the gene SCN5A and hypertensive disorder.